3B BlackBio Dx Limited Confirms Non-Applicability of SEBI Large Corporate Disclosure Requirements

1 min read     Updated on 16 Apr 2026, 09:36 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

3B BlackBio Dx Limited has formally submitted an updated declaration to BSE Limited confirming it does not qualify as a Large Corporate under SEBI regulatory framework. The declaration, submitted on April 15, 2026, with reference number P-66/2026-27/5, was digitally signed by Company Secretary Navneet Kaur and CFO Nikhil Kuber Dubey, exempting the company from specific disclosure requirements under SEBI circular dated October 19, 2023.

powered bylight_fuzz_icon
37716295

*this image is generated using AI for illustrative purposes only.

3b blackbio dx Limited has formally declared to BSE Limited that it does not qualify as a Large Corporate under the Securities and Exchange Board of India (SEBI) regulatory framework, thereby exempting itself from specific disclosure requirements.

Updated Regulatory Compliance Declaration

The company submitted its latest declaration on April 15, 2026, addressing the non-applicability of disclosure requirements outlined in SEBI circular SEBI/HO/DDHS/DDHSRACPOD1/P/CIR/2023/172 dated October 19, 2023. The formal communication was directed to the Department of Corporate Relations at BSE Limited.

Parameter: Details
Reference Number: P-66/2026-27/5
Submission Date: April 15, 2026
SEBI Circular: SEBI/HO/DDHS/DDHSRACPOD1/P/CIR/2023/172
Circular Date: October 19, 2023
Company Status: Formerly Kilpest India Limited

Corporate Authorization

The declaration was duly authorized and digitally signed by key company officials. Company Secretary Navneet Kaur (ACS No. 29130) and Chief Financial Officer Nikhil Kuber Dubey (DIN: 00538049) both provided their digital signatures on April 15, 2026, at 16:14:22 and 16:15:03 respectively.

SEBI Large Corporate Framework

The SEBI circular dated October 19, 2023, establishes specific criteria for categorizing companies as Large Corporates, which triggers additional disclosure obligations. By confirming its non-applicability under these criteria, 3B BlackBio Dx Limited has clarified its regulatory status and compliance obligations to the stock exchange.

The company's formal submission serves as an official record with BSE Limited, ensuring transparency regarding its regulatory classification and associated disclosure requirements under current SEBI guidelines.

Historical Stock Returns for 3B BlackBio DX

1 Day5 Days1 Month6 Months1 Year5 Years
+5.51%+9.45%+6.56%-4.08%-25.85%+304.37%

What growth trajectory would trigger 3B BlackBio Dx Limited to qualify as a Large Corporate under SEBI's framework in the future?

How might this regulatory exemption impact the company's ability to attract institutional investors who prefer enhanced disclosure requirements?

Will 3B BlackBio Dx Limited voluntarily adopt any of the Large Corporate disclosure practices to improve market transparency?

3B BlackBio Dx Limited Files SEBI Compliance Certificate for Q4FY26

1 min read     Updated on 06 Apr 2026, 11:07 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

3B BlackBio Dx Limited submitted its mandatory quarterly certificate under SEBI Depositories Regulations for Q4FY26 to BSE Limited on April 6, 2026. The filing, signed by Whole Time Director Nikhil Kuber Dubey, includes confirmation from RTA Adroit Corporate Services validating proper dematerialization processes and compliance with regulatory requirements for securities handling during the quarter ended March 31, 2026.

powered bylight_fuzz_icon
37042676

*this image is generated using AI for illustrative purposes only.

3B BlackBio Dx Limited has filed its quarterly compliance certificate with BSE Limited, fulfilling mandatory regulatory requirements under SEBI Depositories and Participants Regulations for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The company submitted the certificate on April 6, 2026, in compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. The filing was signed by Nikhil Kuber Dubey, Whole Time Director (DIN: 00538049), and addressed to the Department of Corporate Relations at BSE Limited.

Filing Details: Information
Quarter Ended: March 31, 2026
Filing Date: April 6, 2026
Reference Number: P-66/2026-27/3
Signatory: Nikhil Kuber Dubey, Whole Time Director
DIN: 00538049

RTA Confirmation Certificate

Adroit Corporate Services Pvt. Ltd., serving as the company's Registrar and Share Transfer Agent, provided the confirmation certificate dated April 1, 2026. The RTA confirmed that securities received from depository participants for dematerialization during Q4FY26 were properly processed and confirmed to the depositories.

Key Compliance Confirmations

The RTA certificate validates several critical compliance aspects:

  • Securities received for dematerialization were confirmed (accepted/rejected) to depositories
  • Securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
  • Security certificates received for dematerialization have been mutilated and cancelled after due verification
  • Depository names have been substituted in the register of members as registered owners within 15 days

Corporate Structure

The filing identifies the company as 3B BlackBio Dx Limited (Formerly, Kilpest India Limited), indicating a recent corporate restructuring or name change. The company maintains its registered operations from Bhopal, Madhya Pradesh.

This quarterly certification demonstrates the company's adherence to SEBI's regulatory framework governing depositories and participants, ensuring transparent and compliant securities handling processes throughout Q4FY26.

Historical Stock Returns for 3B BlackBio DX

1 Day5 Days1 Month6 Months1 Year5 Years
+5.51%+9.45%+6.56%-4.08%-25.85%+304.37%

What strategic business changes prompted 3B BlackBio Dx Limited's recent name change from Kilpest India Limited?

How might the company's transition into biotechnology diagnostics impact its financial performance in upcoming quarters?

Will 3B BlackBio Dx Limited require additional regulatory approvals from healthcare authorities given its apparent shift to biotech operations?

More News on 3B BlackBio DX

1 Year Returns:-25.85%